Search Results
Jun 02, 2026, 13:30 ET Dodge Turbocharges Customization and Gasoline Performance for the 2027 Dodge Charger Lineup
Charger multi-energy lineup with standard all-wheel drive (AWD) is led by the gas engine, SIXPACK-powered Dodge Charger R/T and Dodge Charger Scat PackDodge Charger R/T, powered by the twin-turbo SIXPACK engine, produces 420 horsepower, the most standard horsepower of any muscle carDodge
More news about: Stellantis
Jun 02, 2026, 13:00 ET Most Horsepower Per Dollar for Gas SUV, Updated Dodge Durango R/T 392 Leads 2027 Durango HEMI® V-8 Lineup
seatingPerformance lower splitter (Durango R/T 392 Plus and R/T 392 Premium)Expanded customization options:20-by-10-inch Forged Brass Monkey wheelsRed seat beltsYellow Brembo brake calipers (Durango R/T 392 Premium)Durango
More news about: Stellantis
Jun 02, 2026, 12:15 ET 4T2D Gains Visibility and Eliminates Spreadsheets with Centric PLM
Demo4T2D (https://www.4t2d.com/)Based in Burlington, Vermont, 4T2D is an outdoor and
More news about: Centric Software
Jun 02, 2026, 12:10 ET Advanced NanoTherapies sichert sich über 31 Millionen US-Dollar in der Serie-B-Finanzierungsrunde, um eine einzigartige Plattform mit einem mit Nanopartikeln beschichteten Ballon für die vaskuläre Behandlung zu entwickeln, der mit zwei Wirkstoffen (Paclitaxel und Sirolimus) beschichtet ist
US-Dollar bekannt. Die Finanzierungsrunde wurde gemeinsam von einem nicht genannten strategischen Investor und S3 Ventures geleitet, unter Beteiligung des T45-Fonds sowie neuer und bestehender Investoren.
More news about: Advanced NanoTherapies
Jun 02, 2026, 12:03 ET Advanced NanoTherapies desarrollará una plataforma de balón recubierto de nanopartículas con doble fármaco
total de más de 31 millones de dólares. La ronda fue codirigida por un inversor estratégico no revelado y S3 Ventures, con la participación del Fondo T45 y nuevos inversores, tanto existentes como nuevos.
More news about: Advanced NanoTherapies
Jun 02, 2026, 12:00 ET Rise Therapeutics Completes Enrollment in Four-Week Dose Expansion Cohort for the R-2487 Rheumatoid Arthritis Clinical Trial
address underlying immune dysfunction in autoimmune diseases. The therapy works by inducing bystander immune tolerance through modulation of regulatory T cells (Tregs), targeting a core driver of chronic inflammation.This approach represents a novel, disease-modifying mechanism with the potential
More news about: Rise Therapeutics
Jun 02, 2026, 11:39 ET Breakthrough T1D and Sub-Zero Group Foundation Announce National Partnership to Support Type 1 Diabetes Research
disease-modifying therapies that can change the course of T1D, technology to help with day-to-day T1D management, treatments that address complications of T1D, and cell therapies that may one day cure the disease.About Breakthrough T1D, Formerly JDRF As the leading global type 1
More news about: Breakthrough T1D, Formerly JDRF
Jun 02, 2026, 11:31 ET Advanced NanoTherapies obtient plus de 31 millions de dollars de série B pour proposer le premier ballon enrobé de deux médicament (paclitaxel et sirolimus) recouvert de nanoparticules pour le traitement vasculaire.
table a été effectué conjointement par un investisseur stratégique dont l'identité n'a pas été révélée et par S3 Ventures, avec la participation du fonds T45 et d'investisseurs nouveaux et existants.
More news about: Advanced NanoTherapies
Jun 02, 2026, 11:30 ET G50 Corp. Confirms Significant Gold and Silver Mineralization in Parallel Veins over 1.3KM at its Golconda Project in Arizona
intercepts include:15.2m @8.24 g/t Au, 59.9 g/t Ag (near surface) GRC4016.8 m @4.34 g/t Au, 68.8g/t Ag GDD0913.4 m @1.63g/t Au, 31 g/t Ag (incl. 1.5 m @13.25 g/t Au) GDD0412.2 m @0.56 g/t Au, 200g/t Ag CRC39Gallium is consistent across nearly
More news about: G50 Corp Limited
Jun 02, 2026, 11:14 ET DriveNets sichert sich 410 Millionen US-Dollar in einer Serie-D-Finanzierungsrunde, um der steigenden Nachfrage nach Ethernet Fabric in groß angelegten KI-Implementierungen gerecht zu werden
Sekunde und geringeren Kosten pro Token führt. Die Lösungen von DriveNets bilden die Grundlage für Produktionsnetzwerke globaler Tier-1-Betreiber wie AT&T und Comcast und ermöglichen die Skalierung herstellerübergreifender KI-Infrastrukturen in Labors für Grundmodelle, NeoClouds und Unternehmen. Weitere
More news about: Drivenets Ltd.
Jun 02, 2026, 11:08 ET /C O R R E C T I O N -- XNRGY Climate Systems/
More news about: XNRGY Climate Systems
Jun 02, 2026, 11:00 ET Conner Homes Announces Final Opportunities at Richards Ridge Community
T&T Supermarket, the popular Asian foods grocery store.Only three move-in ready homes are now available, ranging in size from 2,956 to 3,040
More news about: Conner Homes
Jun 02, 2026, 11:00 ET WELLCAMP Launches Modular Hospital Solutions for Disaster Relief, Military and Remote Industrial Sites
response scenarios.The program comes in two configurations: the Flat Pack Container Module for rapid containerized deployment, and the Prefab T House for medium to large-scale, temporary to semi-permanent medical complexes. Both scale from a single field medical station to a full hospital campus
More news about: Guangdong WELLCAMP Steel Structure & Modular Housing Co., Ltd.
Jun 02, 2026, 10:30 ET Cardiac Marker Testing Market worth $9.06 billion by 2031 | MarketsandMarkets™
Insights:The reagents & kits segment is expected to register the highest growth rate with 11%.Troponin I & T leads the market with a share of 40.3% in 2025.Lab tests accounted for the largest market share of 74.7% in 2025.Multiplex assay to
More news about: MarketsandMarkets
Jun 02, 2026, 10:00 ET T5 Smackover Partners Signs Offtake Agreement with Glencore for Lithium Carbonate from East Texas Smackover Formation
applications, and the broader energy transition. T5's East Texas project will produce lithium carbonate from direct lithium extraction (DLE) technology, an ancillary biproduct of its geothermal energy plants."Partnering with Glencore brings speed to market for T5 in East Texas. Their global lithium presence
More news about: T5 Smackover Partners
Jun 02, 2026, 09:56 ET FAIRMONT HOTELS & RESORTS DEBUTTA NEL NORD-OVEST DELL'INGHILTERRA CON FAIRMONT CHESHIRE, THE MERE
T. +44(0) 1565 830155Contatto per ristoranti [email protected]T. +44(0) 1565 830155Prenotazioni MICE
More news about: Fairmont Hotels & Resorts
Jun 02, 2026, 09:42 ET Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
Series B financing totaling more than $31 million. The round was co-led by an undisclosed strategic investor and S3 Ventures, with participation from the T45 Fund and new and existing investors.
More news about: Advanced NanoTherapies
Jun 02, 2026, 09:42 ET Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
Series B financing totaling more than $31 million. The round was co-led by an undisclosed strategic investor and S3 Ventures, with participation from the T45 Fund and new and existing investors.
More news about: Advanced NanoTherapies
Jun 02, 2026, 09:31 ET AvenCell Therapeutics to Report Phase 1a Results of First-in-Class Switchable Allogeneic CD123 CAR-T Therapy for AML in Late-Breaking oral presentation at EHA 2026
clinical-stage cell therapy company developing switchable CAR-T therapies for cancer, today announced that data from the completed Phase 1a portion of the RevSTAR-123 study, evaluating AvenCell's investigational switchable allogeneic CAR-T candidate (AVC-201) in patients with CD123-positive relapsed/refractory
More news about: AvenCell Therapeutics, Inc.
Jun 02, 2026, 09:30 ET Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
investigational in vivo CAR-T therapy)Successful in vivo CAR-T generation and minimal residual disease (MRD) clearance with KLN-1010 across diverse baseline T Cell phenotypes in relapsed/refractory
More news about: Eli Lilly and Company
Jun 02, 2026, 09:24 ET CROWN HOLDINGS, INC. APPOINTS OZGUR ATAS PRESIDENT OF ASIA PACIFIC DIVISION
www.crowncork.com.For more information, contact:Thomas T. Fischer, Vice President, Investor Relations and Corporate Affairs, (215) 552-3720
More news about: Crown Holdings, Inc.
Jun 02, 2026, 09:07 ET Metanoia Showcases AI-RAN Ecosystem and Launches Breakthrough 5G Open SDR Platform at COMPUTEX 2026
comprehensive Hardware Design Kits (HDKs) and Semi-Turnkey Software Development Kits (SDKs).The initial product portfolio features:4T4R 24 dBm Indoor O-RU4T4R 5W and 15W FR1 Outdoor O-RUs50 dBm EIRP FR2 Outdoor Radio"MOSART provides operators, OEMs, and ODMs with a flexible
More news about: Metanoia Communications
Jun 02, 2026, 09:02 ET A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
Natural killer cells are part of the body's innate immune system — fast-acting cells that can destroy diseased cells without the priming that conventional T cells require. The challenge has always been pointing them at a tumor reliably. GT Biopharma's TriKE, or tri-specific killer engager, is a single engineered
More news about: USA News Group